ARQT

Arcutis BiotherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$45.00

+116.5% vs current

Most likely

Base case

60%

Probability

Target price

$30.00

+44.3% vs current

B-

Bear case

20%

Probability

Target price

$18.00

-13.4% vs current

AI sentiment snapshot

Latest data as of 2026-01-03

AI commentary

Investor tone is cautiously constructive: market focus is on near-term data/label windows and early commercial uptake. Short-term headlines will drive trading; longer-term sentiment depends on durable prescription growth and reimbursement progress. [#PR-2025][#10-Q]

RankAlpha Sentiment AI - 2026-01-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-03catalystQ4/FY results and guidanceHigh impact

Quarterly and annual results with management guidance; date estimated. Expect near-term volatility around consensus revisions. [#10-Q]

2026-09-30eventRegulatory label expansion decision windowHigh impact

Potential supplemental approval or label-expansion decision; date is an estimated window endpoint. Outcome would materially affect addressable market. [#PR-2025]

2027-01-03catalystCommercial adoption / revenue inflectionHigh impact

Wider U.S. uptake or selective international launches could produce a material revenue inflection; date is a conservative 1-year estimate. [#IR-2025]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-03 • Updated nightlySource: Internal modelMethodology